Clinicopathologic characteristics of mice with chronic myeloid leukemia–like disease or small-bowel syndrome
| ABL oncogene . | Disease . | PB WBC (× 109/L) . | Spleen wt (g) . | Fatty liver . | Pulmonary hemorrhage . | Liver EMH . |
|---|---|---|---|---|---|---|
| p210BCR-ABL | CML-like (n = 10)* | 295 ± 59 | 0.92 ± 0.06 | − | + | + |
| TEL-ABL | CML-like (n = 11)* | 254 ± 47 | 0.74 ± 0.05 | − | + | + |
| TEL-ABL | SBS (n = 26)* | 56 ± 16 | 0.31 ± 0.02 | + | − | − |
| ABL oncogene . | Disease . | PB WBC (× 109/L) . | Spleen wt (g) . | Fatty liver . | Pulmonary hemorrhage . | Liver EMH . |
|---|---|---|---|---|---|---|
| p210BCR-ABL | CML-like (n = 10)* | 295 ± 59 | 0.92 ± 0.06 | − | + | + |
| TEL-ABL | CML-like (n = 11)* | 254 ± 47 | 0.74 ± 0.05 | − | + | + |
| TEL-ABL | SBS (n = 26)* | 56 ± 16 | 0.31 ± 0.02 | + | − | − |
Plus-minus values are means ± SE.
PB indicates peripheral blood; WBC, white blood cell count, and EMH, extramedullary hematopoiesis.
Number of diseased mice analyzed; the data forTEL-ABL-induced CML-like disease and SBS include recipients from additional transplantation experiments that yielded results similar to those in shown in Figure 3.